Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

CML Expert Opinions

Shady Awad 1

Non-BCR-ABL1 molecular biomarkers of prognosis in CML
Dr. Shady Awad, Hematology Research Unit Helsinki,
University of Helsinki (Finland)

  • Clinical heterogeneity and biomarkers in CML
  • Somatic mutations in CP-CML
  • Epigenetic modifier gene mutations in CP-CML
  • CHIP and clonal evolution in CP-CML
  • Somatic mutations in BP-CML
  • Fusion genes and rearrangements in CML
  • Gene expression signatures (GES) as prognosis markers
  • scRNA-sequencing in CML
  • RUNX1 as an example of mutation-induced GES in BP-CML
  • Molecular biomarkers of DMR
  • Epigenetic modifier gene mutations as a biomarker for TFR
  • Challenges and prospets

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022